|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
SNPs in the <i>APOA1/C3/A4/A5-ZPR1-BUD13</i> gene cluster were associated with dyslipidemia.
|
30631647 |
2019 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Seven factors were associated with ICAS, as suggested by the meta-analysis, including advanced age (odds ratio (OR) 1.05, 95% CI 1.03-1.08), metabolic syndrome (OR 2.13, 95% CI 1.35-3.37), diabetes mellitus (OR 1.98, 95% CI 1.69-2.31), hypertension (OR 1.97, 95% CI 1.69-2.31), dyslipidemia (OR 1.29, 95% CI 1.04-1.59), high levels of low-density lipoprotein cholesterol (OR 1.06, 95% CI 1.00-1.12) and high levels of apolipoprotein A1 (OR 0.34, 95% CI 0.15-0.75).
|
30658194 |
2019 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The rs2483058C-rs2580520G haplotype was associated with an increased risk of dyslipidemia, and showed consistent association with serum total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), apolipoprotein (Apo) A1 levels, and the ApoA1/ApoB ratio.
|
28912560 |
2017 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Association of APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) with dyslipidemia in the Kazakhs of Xinjiang.
|
27173266 |
2016 |
|
Dyslipidemias
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A novel PPARδ agonist, PYPEP, suppressed atherosclerotic lesion progression by improving the serum lipoprotein profiles, including increased levels of ApoA-I and functional HDL particles, as well as a reduced non-HDL cholesterol level, in hApoB100/hCETP-dTg mice with human-like hypercholesterolemic dyslipidemia.
|
26683793 |
2016 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Gout is associated with dyslipidaemia.Association of the apolipoprotein A1-C3-A4 gene cluster with gout has previously been reported in a small study.
|
27094595 |
2016 |
|
Dyslipidemias
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of the study was to scrutinize the effect of Clematichinenoside (AR) on dyslipidemia-induced atherosclerosis and explore its capability on expression of Peroxisome proliferator-activated receptor-α (PPAR-alpha), apolipoprotein A-I (APOA1) and A-II (APOA2), and suppression of apolipoprotein C-III (APOC3) genes and proteins.
|
25979856 |
2015 |
|
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
Activation of JNK has been shown to promote insulin resistance and dyslipidemia, including reductions in plasma high-density lipoprotein (HDL) and apolipoprotein A-I (apo A-I).
|
24038215 |
2014 |
|
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
The results showed significant relationships between HDCP and triglycerides, apolipoprotein A1, and high-density lipoprotein cholesterol (P < 0.05), which confirmed that HDCP was accompanied by dyslipidemia.
|
25117371 |
2014 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Thus we reasoned that dyslipidemia-associated nucleotide polymorphisms (SNPs) on the APOA1/C3/A5 gene cluster may predict breast cancer risk and tumor progression.
|
23829168 |
2013 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ApoB rs512535 and ApoA1 rs670 major G allele homozygotes had increased MetS risk (OR 1.65 [CI 1.24, 2.20], P = 0.0006; OR 1.42 [CI 1.08, 1.87], P = 0.013), which may be, partly, explained by their increased abdominal obesity and impaired insulin sensitivity (P<0.05) but not dyslipidemia.
|
21122859 |
2011 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The -1131T-->C polymorphism of the apolipoprotein A-V gene (APO A-V) is tightly linked to lipid metabolism and has been associated with increased triglyceride levels and familial dyslipidemia.
|
16375582 |
2006 |
|
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
While HDL has not been a target for therapy for dyslipidemias, new insight into the major protein component of HDL, apolipoprotein A-I, may lead to new therapies.
|
15529065 |
2005 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We conclude that alterations in apoA-I not only may have adverse effects on HDL biosynthesis but also may promote dyslipidemia due to interference of the apoA-I mutants on the overall cholesterol and triglycerides homeostasis.
|
15751988 |
2005 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Several single nucleotide polymorphisms were described and particular SNP alleles and haplotypes in the APO A-V gene region were shown to be associated with dyslipidemia.
|
12678656 |
2003 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A method to screen apolipoprotein polymorphisms in whole plasma: description of apolipoprotein A-IV variants in dyslipidemias and a reassessment of apolipoprotein A-I in Tangier disease.
|
3105587 |
1987 |